Provided by Tiger Trade Technology Pte. Ltd.

Q32 Bio Inc.

8.34
+0.25003.09%
Post-market: 8.22-0.1200-1.44%18:54 EDT
Volume:854.88K
Turnover:7.05M
Market Cap:247.77M
PE:2.78
High:8.46
Open:8.13
Low:7.94
Close:8.09
52wk High:23.57
52wk Low:1.91
Shares:29.71M
Float Shares:20.90M
Volume Ratio:0.83
T/O Rate:4.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.00
EPS(LYR):2.42
ROE:72.14%
ROA:14.74%
PB:2.34
PE(LYR):3.44

Loading ...

UiPath, Pegasystems, Coinbase, Q32 Bio, BlackLine Trending by Analysts

TIPRANKS
·
Oct 03

Nektar Stock Sinks Despite Promising Hair Loss Treatment Data

Dow Jones
·
Oct 01

Analysts Offer Insights on Healthcare Companies: Q32 Bio (QTTB) and Wave Life Sciences (WVE)

TIPRANKS
·
Oct 01

Q32 Bio Inc trading halted, volatility trading pause

TIPRANKS
·
Sep 30

NASDAQ Trade Halt Volatility Trading Pause at 09:30 Am

Reuters
·
Sep 30

Q32 Bio Reports 36-Week Phase 2a Signal-AA Data Showing 35.3% Mean SALT Score Reduction for Bempikibart in Alopecia Areata

Reuters
·
Sep 30

Q32 Bio Presents Results from Part B of the Signal-Aa Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

THOMSON REUTERS
·
Sep 30

Top Premarket Gainers

MT Newswires Live
·
Sep 30

Top Premarket Gainers

MT Newswires Live
·
Sep 29

Q32 Bio Inc. : Clear Street Initiates Coverage with Buy Rating; Price Target $38

THOMSON REUTERS
·
Sep 29

Jefferies Initiates Q32 Bio at Buy With $29 Price Target

MT Newswires Live
·
Sep 28

Q32 Bio initiated with a Buy at Jefferies

TIPRANKS
·
Sep 28

Q32 Bio to Present 36-Week Phase 2a Signal-AA Trial Data for Bempikibart in Alopecia Areata at EADV 2026

Reuters
·
Sep 22

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the Signal-Aa Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026

THOMSON REUTERS
·
Sep 21

Q32 Bio Names José Trevejo Chief Medical Officer

Reuters
·
Sep 14

Q32 Bio Appoints JosÉ Trevejo, M.d., Ph.d., as Chief Medical Officer and Ellie Hershberger, Pharm.d., as Chief Development Officer

THOMSON REUTERS
·
Sep 14

Q32 Bio on Track for Longest Losing Streak Since November 2024

Dow Jones
·
Sep 09

Q32 Bio to Present at Wells Fargo Healthcare Conference

Reuters
·
Sep 01

Q32 Bio Initiated at Overweight by Morgan Stanley

Dow Jones
·
Aug 24

Q32 Bio initiated with an Overweight at Morgan Stanley

TIPRANKS
·
Aug 24